Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jennifer Ruth Brown, Ph.D., M.D.


This page shows the publications co-authored by Jennifer Brown and Benjamin Lampson.
Connection Strength

  1. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2021 08; 35(4):807-826.
    View in: PubMed
    Score: 0.939
  2. For CLL cells, there's no place like home. Leuk Lymphoma. 2019 12; 60(14):3347-3349.
    View in: PubMed
    Score: 0.828
  3. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174.
    View in: PubMed
    Score: 0.810
  4. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018 03; 11(3):185-194.
    View in: PubMed
    Score: 0.748
  5. PI3Kd-selective and PI3Ka/d-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov; 26(11):1267-1279.
    View in: PubMed
    Score: 0.729
  6. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 05 04; 129(18):2581-2584.
    View in: PubMed
    Score: 0.699
  7. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
    View in: PubMed
    Score: 0.664
  8. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402.
    View in: PubMed
    Score: 0.240
  9. High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Rep. 2021 Jun; 7(6):391-394.
    View in: PubMed
    Score: 0.232
  10. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32.
    View in: PubMed
    Score: 0.211
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.